Skip to content
value.today
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc.

🇺🇸 Bedford, Massachusetts, USABiotechnologyFounded 2014
Total raised
$90 M
1 round on record
Latest round
$90 M
Oct 2018
First round on record
Oct 2018
Today
Went public
See the company page

Stoke Therapeutics, Inc. is listed today as Stoke Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Stoke Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2018$90 MNo. 1$50 to $250 million

Stoke Therapeutics, Inc.: Raise no. 1, Oct 2018

Investors in this round

14 investors had bought by the notice of Nov 2, 2018: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Stoke Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$90 M of $90 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adrian R. Krainer · Executive Officer, Director, Promoter
  • Barry M. Ticho · Executive Officer
  • Charles R. Allerson · Executive Officer
  • Edward M. Kaye · Executive Officer, Director
  • Gene M. Liau · Executive Officer
  • Huw M. Nash · Executive Officer
  • Isabel M. Aznarez · Executive Officer, Promoter
  • Meena R. Meena · Executive Officer
  • Arthur A. Levin · Director
  • Arthur W. Tzianabos · Director
  • Samuel W. Hall · Director
  • Seth L. Harrison · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Edward M. Kaye, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 2, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Stoke Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2018).

    SEC Form D · Nov 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2018

That is all the official record says: Stoke Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Stoke Therapeutics, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Stoke Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Apple Tree Partners IV, L.P.Fund or asset managernot statednot statedHeld Series A, A-2CONVERTIBLE and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ATP III GP, Ltd.Companynot statednot statedHeld Series A, A-2CONVERTIBLE and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
RTW Investments, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Seth Loring HarrisonPersonnot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 14 investors.

Largest shareholders today

Institutions holding Stoke Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Stoke Therapeutics, Inc.
NameRoleNamed in
Adrian R. KrainerExecutive officerNov 2018
Barry M. TichoExecutive officerNov 2018
Charles R. AllersonExecutive officerNov 2018
Edward M. KayeExecutive officerNov 2018
Gene M. LiauExecutive officerNov 2018
Huw M. NashExecutive officerNov 2018
Isabel M. AznarezExecutive officerNov 2018
Meena R. MeenaExecutive officerNov 2018
Adrian R. KrainerDirectorNov 2018
Arthur A. LevinDirectorNov 2018
Arthur W. TzianabosDirectorNov 2018
Edward M. KayeDirectorNov 2018
Samuel W. HallDirectorNov 2018
Seth L. HarrisonDirectorNov 2018
Adrian R. KrainerPromoterNov 2018
Isabel M. AznarezPromoterNov 2018

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.